SFRP5 and hepatocellular carcinoma: We asked whether V3Nter and V3FL could inhibit Wnt/β−catenin signaling in cell lines carrying activating β−catenin mutations, HCT116 (β−catenin ΔS45) and HepG2 (HCC, β−catenin Δ25−140) and used SFRP1 and SFRP5 as controls.